Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402

Journal of Clinical Oncology

Volumn 27, Issue 27, 2009, Pages 4487-4491

  Lilenbaum, Rogerio ^a   Wang, Xiaofei ^a   Gu, Lin ^a   Kirshner, Jeffrey ^a   Lerro, Keith ^a   Vokes, Everett ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CETUXIMAB; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESEARCH; CANCER STATISTICS; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; HYPERSENSITIVITY; INFECTION; LUNG DISEASE; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; SUDDEN DEATH; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PYRAZINES; TAXOIDS;

EID: 76749130692     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.7066     Document Type: Article

References (17)

1. Lilenbaum R: Treatment of advanced non-small-cell lung cancer in special populations. Oncology (Williston Park) 18:1321-1325, 2004
2. Lilenbaum RC, Herndon JE II, List MA, et al: Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (Study 9730). J Clin Oncol 23:190-196, 2005
3. Obasaju CK, Conkling P, Richards D, et al: A randomized phase 3 trial of gemcitabine with or without carboplatin in performance status 2 (PS2) patients (pts) with advanced (stage IIIB with pleural effusion or stage IV) non-small cell lung cancer (NSCLC). J Clin Oncol 25:392s, 2007 (suppl; abstr 7533)
4. Gridelli C, Ardizzoni A, Le Chevalier T, et al: Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: Results of a European Experts Panel. Ann Oncol 15:419-426, 2004
5. NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (Version 2.2008). 2008 National Comprehensive Cancer Network. http://www.nccn.org
6. Lilenbaum R, Rubin M, Samuel J, et al: A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol 2:306-311, 2007
7. Hesketh PJ, Chansky K, Wozniak AJ, et al: Erlotinib as initial therapy in patients with advanced non-small cell lung cancer patients and a performance status of 2: A SWOG phase II trial (S0341). J Clin Oncol 25:393s, 2007 (suppl; abstr 7536)
8. Lilenbaum R, Axelrod R, Thomas S, et al: Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-smallcell lung cancer and a performance status of 2. J Clin Oncol 26:863-869, 2008
9. Morere J, Westeel V, Morin F, et al: Randomized phase II trial of first-line gefitinib, gemcitabine, or docetaxel in performance status 2 or 3 non-small-cell lung cancer patients (IFCT-0301). J Clin Oncol 26:445s, 2008 (suppl; abstr 8086)
10. Pirker R, Szczesna A, von Pawel J, et al: FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer. J Clin Oncol 26:6s, 2008 (suppl; abstr 3)
11. Kim ES, Mauer AM, William WN Jr, et al: A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced non-small cell lung cancer. Cancer 115:1713-1722, 2009
12. Fanucchi MP, Fossella FV, Belt R, et al: Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24:5025-5033, 2006
13. Hanna N, Lilenbaum R, Ansari R, et al: Phase II trial of cetuximab in patients with previously treated non-small cell lung cancer. J Clin Oncol 24:5253-5258, 2006
14. Dreicer R, Petrylak D, Aqus D, et al: Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 13:1208-1215, 2007
15. Davies AM, McCoy J, Lara PN, et al: Bortezomib + gemcitabine (Gem)/carboplatin (Carbo) results in encouraging survival in advanced non-small cell lung cancer (NSCLC): Results of a phase II Southwest Oncology Group (SWOG) trial (S0339). J Clin Oncol 24:368s, 2006 (suppl; abstr 7017)
16. Sweeney CJ, Zhu J, Sandler AB, et al: Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase II trial in patients with metastatic non-small cell lung carcinoma. Cancer 92:2639-2647, 2001
17. Wheatley-Price P, Shepherd F: Targeting angiogenesis in the treatment of lung cancer. J Thorac Oncol 10:1173-1184, 2008